Rising Knee And Hip Replacement Surgeries Driving The Market Due To Increasing Risk Of Post-Surgical Bone Complications Emerges as a Core Driver of the Avascular Necrosis Market in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Avascular Necrosis Market Through 2025?
The market size for avascular necrosis has significantly expanded over the recent years. There is expected growth from $0.81 billion in 2024 to $0.89 billion in 2025, representing a compound annual growth rate (CAGR) of 9.7%. Factors like a growing elderly population, increased alcohol intake, advancements in sports medicine, increased medical tourism, and precision medicine have contributed to the growth witnessed in the past.

What's the Projected Size of the Global Avascular Necrosis Market by 2029?
The market size for avascular necrosis is anticipated to experience considerable growth in the upcoming years, reaching $1.27 billion by 2029 with a compound annual growth rate (CAGR) of 9.3%. This projected growth during the forecast period can be linked to factors such as an increased number of osteonecrosis cases related to corticosteroid use, an increased number of knee and hip surgeries, an increased number of drug approvals, an increased number of car accidents, and growing instances of bone injuries. Key trends during the forecast period include technological improvements, advanced imaging technologies, AI-driven diagnostics, 3D-printed surgical implants, regenerative orthobiologics, and cellular therapies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/avascular-necrosis-global-market-report

Top Growth Drivers in the Avascular Necrosis Industry: What's Accelerating the Market?
The avascular necrosis market is expected to experience substantial growth due to the increasing rates of knee replacement and hip surgeries. These surgeries, which involve replacing damaged joints, are essential to alleviating substantial pain experienced by patients with severe cases of avascular necrosis. The high prevalence of osteoarthritis, known for causing debilitating joint pain and mobility problems, is contributing to a rise in these surgeries, often deemed necessary for pain alleviation and an improved quality of life. Avascular necrosis, which results in bone tissue death due to decreased blood flow and subsequent joint degradation and failure, heightens the requirement for these surgeries. For example, in September 2023, Curvo Labs, Inc., a healare technology firm in the U.S., reported that the number of knee replacement surgeries in the U.S. rose from 1,235,835 in 2021 to 1,299,084 in 2022. Thus, the increasing necessity for knee replacement and hip surgeries is bolstering the expansion of the avascular necrosis market. In addition, the avascular necrosis market is expected to gain momentum with the increase in healare spending, a factor that's likely to foster improved diagnostic and treatment options. Healare spending encompasses the total expenses on health services, treatments, and medical products in a particular demographic or healare system. This spending is on the rise due to the higher prevalence of chronic diseases that necessitate continuous management, regular hospital visits, and expensive medication. Healare spending promotes early diagnosis, advanced treatment, and surgical interventions that help in managing avascular necrosis and enhancing patient outcomes. For instance, the American Medical Association reported in April 2025 that U.S. health expenditure increased by 7.5% in 2023 to $4.9 trillion or $14,570 per capita, a substantial rise from the 4.6% increase in 2022. Hence, the growing healare expenditure is significantly contributing to the expansion of the avascular necrosis market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24476&type=smp

What Trends Will Shape the Avascular Necrosis Market Through 2029 and Beyond?
Key players in the avascular necrosis market are working towards gaining regulatory authorizations in order to broaden their product offerings, increase treatment alternatives, and consolidate their position in the market. These authorizations are formal endorsements given by health bodies that permit a medical item or procedure to be marketed and used, given they meet the requisite safety and efficacy criteria. For example, Regrow Biosciences, a biotech firm based in India, was granted a green light from the United States Food and Drug Administration in May 2022 to carry out Phase II clinical trials in the United States for their orphan drug, OSSGROW, aimed at treating osteonecrosis (also known as avascular necrosis). A groundbreaking, personalized bone cell therapy for the healing treatment of early to moderate phases (up to Stage III) of avascular necrosis (AVN) has been developed by Regrow Biosciences, named OSSGROW. This therapy utilizes the patient's own bone marrow, from which mesenchymal stem cells are separated and then nursed in a specific lab to result in bone-forming cells, referred to as osteoblasts. OSSGROW is seen as a natural, safe, and potentially lasting solution, intending to substitute conventional treatments and joint replacement operations which merely manage symptoms.

What Are the Main Segments in the Avascular Necrosis Market?
The avascular necrosis market covered in this report is segmented -

1) By Type: Trauma Related Avascular Necrosis, Non-Trauma Related Avascular Necrosis
2) By Diagnosis: Imaging, Biopsy, Computed Tomography Scan, Positron Emission Tomography, X-Ray
3) By Treatment Type: Medications, Surgery, Physical Therapy, Lifestyle Changes, Bone Grafting
4) By End-User: Hospitals, Specialty Clinics, Rehabilitation Centers, Ambulatory Surgical Centers, Home Care Settings

Subsegment:
1) By Trauma-Related Avascular Necrosis: Fracture-Induced Avascular Necrosis, Dislocation-Induced Avascular Necrosis, Post-Surgical Avascular Necrosis, Crush Injury-Related Avascular Necrosis, Sports Injury-Associated Avascular Necrosis
2) By Non-Trauma Related Avascular Necrosis: Steroid-Induced Avascular Necrosis, Alcohol-Induced Avascular Necrosis, Sickle Cell Disease-Associated Avascular Necrosis, Lupus-Related Avascular Necrosis, Radiation Therapy-Induced Avascular Necrosis, Idiopathic Avascular Necrosis

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24476&type=smp

Which Top Companies are Driving Growth in the Avascular Necrosis Market?
Major companies operating in the avascular necrosis market are Stryker Corporation, Massachusetts General Hospital, Zimmer Biomet Holdings Inc., Smith & Nephew plc, Stanford Health Care, Apollo Hospitals Enterprise Limited, Singapore General Hospital Pte Ltd., Fortis Healare Limited, Narayana Hrudayalaya Limited, Bumrungrad International Hospital Co. Ltd., Aster DM Healare Limited, Mount Elizabeth Hospital Pte Ltd., Gleneagles Hospital Pte Ltd., Shalby Limited, Texas Orthopedic Hospital LLC, Regrow Biosciences Pvt. Ltd., Maxcure Hospitals Limited, Medicover Hospitals Private Limited, Mesoblast Limited, Athersys Inc., Ginger Healare Private Limited

Which Regions Will Dominate the Avascular Necrosis Market Through 2029?
North America was the largest region in the avascular necrosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the avascular necrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24476

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.